Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Present and Future Perspective on PLK1 Inhibition in Cancer Treatment
Michela Chiappa, Serena Petrella, Giovanna Damia, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 83

Showing 1-25 of 83 citing articles:

A new wave of innovations within the DNA damage response
Qi Li, Wenyuan Qian, Yang Zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 56
Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study
Daniel H. Ahn, Afsaneh Barzi, Maya Ridinger, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 10, pp. 2039-2047
Open Access | Times Cited: 20
New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives
Viola Previtali, Greta Bagnolini, Andrea Ciamarone, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 14, pp. 11488-11521
Open Access | Times Cited: 17
CCNE1andPLK1Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
Ángel Guerrero‐Zotano, Stefania Belli, Christoph Zielinski, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 8, pp. 1557-1568
Open Access | Times Cited: 28
Targeted delivery of polo-like kinase 1 siRNA nanoparticles using an EGFR-PEG bispecific antibody inhibits proliferation of high-risk neuroblastoma.
Amy Logan, Christopher B. Howard, Pie Huda, et al.
Journal of Controlled Release (2024) Vol. 367, pp. 806-820
Closed Access | Times Cited: 8
Cyclers’ kinases in cell division: from molecules to cancer therapy
Giacomo Milletti, Valeria Colicchia, Francesco Cecconi
Cell Death and Differentiation (2023) Vol. 30, Iss. 9, pp. 2035-2052
Open Access | Times Cited: 15
Exploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review
Karam Ashouri, Alexandra C. Wong, Pooja Mittal, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2796-2796
Open Access | Times Cited: 5
Lights and Shadows on the Cancer Multi-Target Inhibitor Rigosertib (ON-01910.Na)
Ana Monfort‐Vengut, Guillermo de Cárcer
Pharmaceutics (2023) Vol. 15, Iss. 4, pp. 1232-1232
Open Access | Times Cited: 11
The Role of Polo-Like Kinase 1 in Regulating the Forkhead Box Family Transcription Factors
Xavier T.R. Moore, Lilia Gheghiani, Zheng Fu
Cells (2023) Vol. 12, Iss. 9, pp. 1344-1344
Open Access | Times Cited: 11
PLK1 and PARP positively correlate in Middle Eastern breast cancer and their combined inhibition overcomes PARP inhibitor resistance in triple negative breast cancer
Abdul K. Siraj, Poyil Pratheeshkumar, Divya Padmaja, et al.
Frontiers in Oncology (2024) Vol. 13
Open Access | Times Cited: 4
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas
Michela Chiappa, Alessandra Decio, Luca Guarrera, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 7
Open Access | Times Cited: 4
MYC and HSF1 Cooperate to Drive Sensitivity to Polo-like Kinase 1 Inhibitor Volasertib in High Grade Serous Ovarian Cancer
Imade Williams, Matthew R. O’Malley, Haddie DeHart, et al.
Cancer Research Communications (2025)
Open Access
Accelerating discovery of bioactive ligands with pharmacophore-informed generative models
Weixin Xie, Jianhang Zhang, Qin Xie, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Optimizing Peptide-Conjugated Lipid Nanoparticles for Efficient siRNA Delivery across the Blood–Brain Barrier and Treatment of Glioblastoma Multiforme
Haiyang Tong, Zesen Ma, Jin Yu, et al.
ACS Chemical Biology (2025)
Closed Access
Onvansertib exhibits anti-proliferative and anti-invasive effects in endometrial cancer
Nikita Sinha, Xiaochang Shen, Jennifer Haag, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Differential Response and Resistance to KRAS‐Targeted Therapy
Zhaojin Liu, Heinz‐Josef Lenz, Jian Yu, et al.
Molecular Carcinogenesis (2025)
Closed Access
Construction of a Colorectal Cancer Prognostic Risk Model and Screening of Prognostic Risk Genes Using Machine-Learning Algorithms
Xuezhi Du, Han Qi, Wenbin Ji, et al.
Computational and Mathematical Methods in Medicine (2022) Vol. 2022, pp. 1-20
Open Access | Times Cited: 17
Mitotic kinases are emerging therapeutic targets against metastatic breast cancer
Alexandra N. Aquino-Acevedo, Joel A. Orengo-Orengo, Melanie E. Cruz-Robles, et al.
Cell Division (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 3
Onvansertib and Navitoclax Combination as a New Therapeutic Option for Mucinous Ovarian Carcinoma
Serena Petrella, Marika Colombo, Mirko Marabese, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 472-472
Open Access
Upregulation of phosphatase and tensin homolog deleted on chromosome ten inhibits lung cancer cell proliferation by suppressing the oncogene polo-like kinase 1 and inducing autophagy
Wei-Zhou Jiang, Pei Wang, Limin Huang
CytoJournal (2025) Vol. 22, pp. 10-10
Open Access
Conservation of OFD1 Protein Motifs: Implications for Discovery of Novel Interactors and the OFD1 Function
Przemysław Jagodzik, Ewa Ziętkiewicz, Zuzanna Bukowy‐Bieryłło
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1167-1167
Open Access
Cyclin E1 overexpression sensitizes ovarian cancer cells to WEE1 and PLK1 inhibition
Qian Xi, Akiko Kunita, Miho Ogawa, et al.
Oncogene (2025)
Open Access
Discovery of a novel PLK1 inhibitor with high inhibitory potency using a combined virtual screening strategy
Zhen Xu, Lixia Guan, Yuting Wang, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2025) Vol. 40, Iss. 1
Open Access
Transcriptome Analysis of Canine Histiocytic Sarcoma Tumors and Cell Lines Reveals Multiple Targets for Therapy
Alexander I. Engleberg, Ya-Ting Yang, Peter Z. Schall, et al.
Cancers (2025) Vol. 17, Iss. 6, pp. 954-954
Open Access
Targeting PLK1-CBX8-GPX4 axis overcomes BRAF/EGFR inhibitor resistance in BRAFV600E colorectal cancer via ferroptosis
Zhan Zhao, Jiashuai He, Shenghui Qiu, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top